Sera Prognostics stock analysis
Want to see SERA full AI Analyst Report?
Sera Prognostics (SERA) Stock Price & Analysis
SERA Stock Chart & Stats
- Day’s Range
- $1.95 - $2.04
- 52-Week Range
- $1.56 - $3.85
- Previous Close
- $1.98
- Volume
- N/A
- Average Volume (3M)
- 31.23K
- Market Cap
- $79.94M
- Enterprise Value
- $65.34M
- Total Cash (Recent Filing)
- $44.09M
- Total Debt (Recent Filing)
- $3.27M
- Price to Earnings (P/E)
- ―
- Beta
- 1.48
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Medicaid Reimbursement
State Medicaid coverage creates a durable reimbursement pathway for PreTRM and materially expands the reachable patient base. The newly covered lives can support repeat utilization and provide a foundation for broader payer adoption as Sera demonstrates clinical and economic value.
Commercial Momentum
Rapid growth in ordering physicians and test volume indicates that PreTRM is moving beyond development toward commercial adoption. If this momentum continues through payer activation and provider implementation, it can improve utilization, strengthen market position, and support operating leverage.
Liquidity Runway
A stated cash runway into fiscal year 2029 gives management time to expand commercialization, pursue reimbursement, and develop international opportunities without immediate financing pressure. This supports strategic continuity while the company works toward higher recurring test volumes.
Bears Say
Persistent Losses
The very small and volatile revenue base remains far below the company’s cost structure, while negative gross profit and large operating losses show that scale has not yet been achieved. Sustained losses could delay self-funded growth until reimbursement converts into meaningful volume.
Cash Burn
Sustained negative operating and free cash flow means commercialization is consuming substantial capital before the business produces internal funding. Unless revenue scales or costs decline, continued burn can reduce financial flexibility and increase reliance on future capital resources.
Slow Provider Adoption
The lengthy provider implementation cycle can postpone the conversion of coverage wins and physician interest into recurring, high-volume testing. This makes near-term revenue growth dependent on sustained field support and patient adoption while practices gradually incorporate PreTRM into routine care.
Sera Prognostics News
Sera Prognostics’ PreTRM Test shows efficacy guiding first-time pregnancy care
Sera Prognostics (SERA) announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM Test-guided care in first-time pregnancies significantly improved neonatal outcomes,
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
What is Sera Prognostics’s market cap?
When is Sera Prognostics’s upcoming earnings report date?
How were Sera Prognostics’s earnings last quarter?
Is Sera Prognostics overvalued?
Does Sera Prognostics pay dividends?
What is Sera Prognostics’s EPS estimate?
How many shares outstanding does Sera Prognostics have?
What happened to Sera Prognostics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sera Prognostics?
What is the TipRanks Smart Score and how is it calculated?
Sera Prognostics Stock Smart Score
Company Description
Sera Prognostics
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Zhenya Lindgardt
- Employees
- 72
- Website
- www.sera.com
- Address
- 2749 East Parleys Way, Salt Lake City, UT, 84109, US
Sera Prognostics (SERA) Earnings & Revenues
SERA Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with substantial increases in ordering physicians and test volume, Medicaid coverage established in Illinois and Florida, expanding commercial and payer engagement, strengthening clinical and health economic evidence, and a stated cash runway into fiscal year 2029. The main challenges were lower third-quarter ASPs caused by a low- or non-reimbursed patient mix and the 12-month to 18-month timeframe typically required to move providers toward broad adoption. Management characterized the company as transitioning into commercialization with significant work still ahead.
View all SERA earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |









